Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.
Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is already elevated by obesity, gallstones and alcohol. That said, the labels carry the warning, and the presentation is distinctive enough to act on: severe persistent upper-abdominal pain radiating to the back, usually with vomiting, not relieved by anything.
Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.
The question I want answered is what the pooled safety data actually shows for this class, as opposed to what the label warning implies. Not looking for reassurance. Looking for the part I have got wrong.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
Dr.MetabolicMD said:Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…
Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk. All readings have been normal:
- Baseline: 44 U/L
- Month 3: 33 U/L
- Month 6: 37 U/L
- Month 9: 35 U/L
Normal range is 0-160 U/L. While clinical pancreatitis is rare (<0.5%), I find peace of mind in regular monitoring. Worth asking your doctor about if you're on a GLP-1 long-term.
Dr.MetabolicMD said:Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is…
Pancreatitis scare with pancreatitis risk: had severe upper abdominal pain radiating to my back at week 6. Went to the ER — they checked lipase and amylase, both normal. Turned out to be severe constipation.
But I'm glad I went. The risk of pancreatitis, while small (<0.5%), is real. Don't try to tough out severe abdominal pain on a GLP-1 agonist. Get checked.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsShort answer first, then the reasoning. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.
JessicaH_TX said:Lipase monitoring while on pancreatitis risk: my doctor checks lipase every 3 months given the theoretical pancreatitis risk.
This matches mine closely enough to be worth saying so out loud.